QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.40 (-3.90%)
BABA   78.61 (-2.91%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.41%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.54%)
AMC   4.63 (-0.22%)
PFE   37.02 (-1.54%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.40 (-3.90%)
BABA   78.61 (-2.91%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.41%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.54%)
AMC   4.63 (-0.22%)
PFE   37.02 (-1.54%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.40 (-3.90%)
BABA   78.61 (-2.91%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.41%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.54%)
AMC   4.63 (-0.22%)
PFE   37.02 (-1.54%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.40 (-3.90%)
BABA   78.61 (-2.91%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.41%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.54%)
AMC   4.63 (-0.22%)
PFE   37.02 (-1.54%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
NASDAQ:DARE

Daré Bioscience (DARE) Stock Forecast, Price & News

$1.01
+0.03 (+3.06%)
(As of 05/30/2023 ET)
Compare
Today's Range
$0.96
$1.02
50-Day Range
$0.97
$1.06
52-Week Range
$0.82
$1.47
Volume
266,849 shs
Average Volume
259,522 shs
Market Capitalization
$87.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Daré Bioscience MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
593.1% Upside
$7.00 Price Target
Short Interest
Healthy
0.44% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.69mentions of Daré Bioscience in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.33) to ($0.41) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

695th out of 1,009 stocks

Pharmaceutical Preparations Industry

352nd out of 494 stocks


DARE stock logo

About Daré Bioscience (NASDAQ:DARE) Stock

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.

Receive DARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Daré Bioscience and its competitors with MarketBeat's FREE daily newsletter.

DARE Stock News Headlines

The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty
A unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.
Everybody Wants a Piece of The Dare
Maxim Group Reaffirms Their Buy Rating on Daré Bioscience (DARE)
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty
A unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.
H.C. Wainwright Remains a Buy on Daré Bioscience (DARE)
Recap: Dare Bioscience Q1 Earnings
Earnings Outlook For Dare Bioscience
Daré Bioscience (DARE) to Release Earnings on Thursday
Track Covid-19 in Dare County, North Carolina
See More Headlines
Receive DARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Daré Bioscience and its competitors with MarketBeat's FREE daily newsletter.

DARE Company Calendar

Last Earnings
3/30/2023
Today
5/30/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DARE
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+612.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-30,950,000.00
Pretax Margin
-305.92%

Debt

Sales & Book Value

Annual Sales
$10 million
Book Value
$0.13 per share

Miscellaneous

Free Float
82,834,000
Market Cap
$84.81 million
Optionable
Not Optionable
Beta
1.20

Key Executives

  • Sabrina Martucci Johnson
    President, CEO, Secretary & Director
  • Mark Walters
    Vice President-Operations
  • Lisa Walters-Hoffert
    Chief Financial Officer
  • Christine Mauck
    Medical Director
  • David Friend
    Chief Scientific Officer













DARE Stock - Frequently Asked Questions

Should I buy or sell Daré Bioscience stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Daré Bioscience in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DARE shares.
View DARE analyst ratings
or view top-rated stocks.

What is Daré Bioscience's stock price forecast for 2023?

4 Wall Street research analysts have issued twelve-month price objectives for Daré Bioscience's stock. Their DARE share price forecasts range from $7.00 to $7.00. On average, they anticipate the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 612.3% from the stock's current price.
View analysts price targets for DARE
or view top-rated stocks among Wall Street analysts.

How have DARE shares performed in 2023?

Daré Bioscience's stock was trading at $0.83 at the beginning of the year. Since then, DARE stock has increased by 18.4% and is now trading at $0.9828.
View the best growth stocks for 2023 here
.

Are investors shorting Daré Bioscience?

Daré Bioscience saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 378,600 shares, a drop of 25.9% from the April 30th total of 511,000 shares. Based on an average trading volume of 191,300 shares, the days-to-cover ratio is currently 2.0 days.
View Daré Bioscience's Short Interest
.

When is Daré Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our DARE earnings forecast
.

How were Daré Bioscience's earnings last quarter?

Daré Bioscience, Inc. (NASDAQ:DARE) posted its earnings results on Thursday, March, 30th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.04.

What other stocks do shareholders of Daré Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Daré Bioscience investors own include FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Matinas BioPharma (MTNB), Novavax (NVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Sorrento Therapeutics (SRNE).

What is Daré Bioscience's stock symbol?

Daré Bioscience trades on the NASDAQ under the ticker symbol "DARE."

Who are Daré Bioscience's major shareholders?

Daré Bioscience's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.73%), Renaissance Technologies LLC (0.66%), State Street Corp (0.29%), Jane Street Group LLC (0.09%) and Virtu Financial LLC (0.04%).
View institutional ownership trends
.

How do I buy shares of Daré Bioscience?

Shares of DARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Daré Bioscience's stock price today?

One share of DARE stock can currently be purchased for approximately $0.98.

How much money does Daré Bioscience make?

Daré Bioscience (NASDAQ:DARE) has a market capitalization of $84.81 million and generates $10 million in revenue each year. The biotechnology company earns $-30,950,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

How can I contact Daré Bioscience?

Daré Bioscience's mailing address is 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122. The official website for the company is www.darebioscience.com. The biotechnology company can be reached via phone at (858) 926-7655, via email at innovations@darebioscience.com, or via fax at 617-494-1544.

This page (NASDAQ:DARE) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -